https://orcid.org/0000-0002-2798-9459
Figures & data
Figure 1. Clinical, molecular, and radiological summary of our patient. (a). An illustrated summary of the treatment regimen received by the patient including best response and progression-free survival in each line of treatment. Hematoxylin-eosin staining illustrating the diagnosis of adenocarcinoma (magnification 400X). Chest computed tomography (CT) scans of the patient from baseline (b), at evaluation of partial response (PR) within 2 months of crizotinib therapy (c), at PD after 11 months of crizotinib therapy (d), at PD after 12 months of brigatinib therapy (e), at SD after 2 months of lorlatinib therapy (f) and at PD after 9 months of lorlatinib therapy (g)
Figure 2. Illustration of the novel ALK G1202L mutation detected from the patient at PD from brigatinib therapy. ALK G1202L is a missense mutations resulting from dinucleotide substitution in the exon 23 of the ALK gene (NM_004304.4:c.3604_3605delGGinsCT p.Gly1202Leu). Green column represents reads with c.3605 G > T, while orange column represents reads with c.3604 G > C. Each gray row represents the sequencing read from a DNA fragment. Bottom bar shows the protein sequence annotation of ALK
